PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) agents, have considerably improved the survival of driver gene wild-type advanced NSCLC (8–10).